Medications That Cause Urinary Retention

High-Risk Medication Classes

The American Urological Association recommends that antimuscarinic medications, including oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium, be used with caution in patients with pre-existing bladder outlet obstruction, benign prostatic hyperplasia, or history of urinary retention 1, 2, 3
The American Urological Association suggests that men with benign prostatic hyperplasia should have antimuscarinic medications prescribed only with extreme caution 1, 2, 3

Patients with diabetes mellitus, prior abdominal surgery, Parkinson's disease, multiple sclerosis, hypothyroidism, and scleroderma require additional caution when using antimuscarinic medications due to increased risk of urinary retention 2, 3

The American Urological Association recommends that antimuscarinic medications should not be used in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist 1
The American Urological Association suggests that a post-void residual (PVR) measurement may be useful in any patient suspected of higher risk of urinary retention before initiating anticholinergic therapy 1
Beta-3 agonists, such as mirabegron and vibegron, are typically preferred before antimuscarinic medications due to lower urinary retention risk 2, 3
The European Association of Urology notes that combination therapy with antimuscarinics and alpha-blockers in men with BPH and overactive bladder may increase the incidence of urinary retention 4

The American Urological Association recommends avoiding anticholinergic escalation in patients experiencing incomplete bladder emptying, as this worsens retention 1, 2
The American Urological Association suggests monitoring for cognitive effects, as antimuscarinics are associated with increased risk of dementia and cognitive impairment, particularly with chronic use 2, 3

Spinal cord injuries or lesions affecting sacral nerves S2-S4 can cause urinary retention 5
Multiple sclerosis and Parkinson's disease are associated with an increased risk of urinary retention 6
Cerebrovascular accidents (stroke) affect approximately 25-50% of stroke survivors, leading to urinary retention 7

Sympathomimetic agents like lisdexamfetamine can stimulate alpha-adrenergic receptors in the bladder neck and urethra, increasing the risk of urinary retention 8

Assessment for risk factors such as male gender, advanced age, and pre-existing lower urinary tract symptoms is crucial in evaluating urinary retention 8
Anticholinergic medications for overactive bladder should be used with extreme caution in patients with impaired gastric emptying or history of urinary retention 9
OnabotulinumtoxinA may be offered to neurogenic lower urinary tract dysfunction (NLUTD) patients who are refractory to oral medications, but patients must be counseled about the 20.49% risk of urinary retention 10, 11

Sphincterotomy may be offered to facilitate emptying in selected male patients with NLUTD, though there is high risk of failure 6

A stepwise approach starting with behavioral bladder-training program, limiting fluids in early evening, and progressing to medication only when needed is recommended for post-stroke urinary retention 7

Amitriptyline carries a high risk of urinary retention because its tertiary‑amine structure confers potent anticholinergic activity that directly impairs detrusor muscle contractility, leading to obstructive voiding. (National Comprehensive Cancer Network) 12
Secondary‑amine tricyclic antidepressants (nortriptyline, desipramine) are better‑tolerated alternatives; they exhibit markedly fewer anticholinergic adverse effects, including reduced incidence of urinary hesitancy. (National Comprehensive Cancer Network) 12

Duloxetine is associated with a very low incidence of urinary retention; clinical trial data show obstructive voiding symptoms in only about 1 % of patients, comparable to placebo rates. (National Comprehensive Cancer Network) 12

First‑line choice for neuropathic pain in elderly men or patients with benign prostatic hyperplasia (BPH) should be duloxetine (30–60 mg daily) rather than amitriptyline, to minimize retention risk. (National Comprehensive Cancer Network; Diabetes/Metabolism Research and Reviews) [12][13]
If a tricyclic antidepressant is required, initiate nortriptyline or desipramine (starting dose 10–25 mg) instead of amitriptyline because of their superior tolerability regarding urinary function. (National Comprehensive Cancer Network) 12

All anticholinergic agents (e.g., antimuscarinics for overactive bladder, anticholinergic respiratory drugs, antipsychotics with anticholinergic properties) should be discontinued or avoided when a patient is started on amitriptyline or duloxetine to prevent additive risk of urinary retention. (National Comprehensive Cancer Network) 12
If urinary retention develops, the offending antidepressant should be stopped immediately, and bladder catheterization performed as needed, with preference for intermittent over indwelling catheters to reduce infection risk. (National Comprehensive Cancer Network) 12